Menu Search
Equities

MedCap AB (publ)

61MA:DEU

MedCap AB (publ)

Actions
  • Price (EUR)43.00
  • Today's Change0.40 / 0.94%
  • Shares traded0.00
  • 1 Year change+61.05%
  • Beta--
Data delayed at least 15 minutes, as of May 16 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MedCap AB (publ) is a Sweden-based private equity company engaged in investments in and development of companies active primarily within the medical equipment sector. The Company reports four segments: Abilia, Unimedic, Quickels and Inpac. The Company’s portfolio includes such companies as Abilia AB, which is engaged in the development and marketing of aids within the fields of communication, cognition, noise and environmental control; Unimedic AB, engaged in contract manufacturing of liquid pharmaceuticals; Quickels Systems AB, which is engaged in the development and marketing of intensive medical care equipment, such as care bags and electrocardiogram (ECG) equipment; AirContainer Package System AB that offers a wide range of packaging solutions for the pharmaceutical industry, and Dunmedic AB, which offers medical products, medicines and food supplements.

  • Revenue in SEK (TTM)1.67bn
  • Net income in SEK203.30m
  • Incorporated2001
  • Employees512.00
  • Location
    MedCap AB (publ)Engelbrektsgatan 9-1STOCKHOLM 114 32SwedenSWE
  • Phone+46 8347110
  • Websitehttps://www.medcap.se/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		MCAP:STO since
announced		Transaction
value
SurgiCube International BVAnnounced24 Jul 202324 Jul 2023Announced93.52%--
Data delayed at least 15 minutes, as of May 17 2024 17:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.